Association for Molecular Pathology (AMP)

Irvine, CA — November 7, 2017 — ResearchDx will be at the Association for Molecular Pathology (AMP) in Salt Lake City, Utah, November 16-18, 2017. Please visit us at booth 608 or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.

Read More

ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers

Irvine, CA—October 2, 2017—ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and […]

Read More

Finding Needles in the Tumor Haystack: Single Cell HER2 Testing with DEPArray™ NxT Technology

Inside the heterogeneous tumor tissue samples sent to clinical pathology laboratories for HER2 gene testing are cancer genomes with their own inherent complexity. The biopsy (or surgical excision) tissue represents a mixture of genomes from the tumor and normal stroma. Further compounding the heterogeneity problem, tumor genomes harboring HER2 gene amplifications may have amplified HER2 […]

Read More

ResearchDx, Inc. and PacificDx Expand Existing Clinical Laboratory and Office Space to Accommodate New Research Partners and Assays

Leading contract diagnostics organization has completed construction of a 12,000 square foot addition to their office in Irvine, CA creating a 30,000 square foot headquarters in Irvine, CA. Irvine, CA—February 1, 2017—ResearchDx, Inc. announced today that construction is completed on a major addition to their Orange County headquarters. The company’s building at 5 Mason in […]

Read More

ResearchDx, Inc. and PacificDx Expand Clinical CLIA Laboratory and Office Space to Accommodate New Research Partners and Assays

ResearchDx, Inc. and PacificDx Expand Clinical CLIA Laboratory and Office Space to Accommodate New Research Partners and Assays  Leading contract diagnostics organization has completed construction of a 12,000 square foot addition to their office in Irvine, CA creating a 30,000 square foot headquarters in Irvine, CA. ResearchDx, Inc. announced the completion of a major construction […]

Read More

Guidelines to the Galaxy of HER2 Testing in GEA Cancers

Say the words “HER2 gene amplification” and what immediately comes to mind is breast cancer. But did you know other cancers, including those of the stomach and esophagus (collectively called gastroesophagel adenocarinoma or GEA) can have too many (> 6) copies of the HER2 gene? That’s right, an estimated 20% of GEA cancers harbor an […]

Read More

ResearchDx/PacificDx to Present High-Resolution HER2 Testing Data at the San Antonio Breast Cancer Symposium

Leading contract diagnostics organization demonstrates the value of DNA-based testing for identifying the HER2-Low genomic subtype in high-risk HER2 equivocal breast cancer Irvine, CA—December 1, 2016—ResearchDx/PacificDx announced today that it will share findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in breast cancer patients at this year’s San […]

Read More

ResearchDx And BioSmartSA Announce New Consulting Practice in Saudi Arabia

Irvine, California and Riyadh, Saudi Arabia, May 17, 2016 — ResearchDx, the premier Contract Diagnostics Organization (CDO) for the biopharmaceutical industry, and BioSmartSA, a healthcare consultancy based in Saudi Arabia, have formed a partnership to bring their expertise in navigating the design and management of diagnostic services to healthcare providers in the Kingdom of Saudi Arabia […]

Read More

A Single Blood Test for All Cancers?

What if a simple blood test could detect any cancer early, when it was still easy to treat? It sounds like science fiction. But Illumina ILMN +5.20%, the $24 billion (market cap) biotechnology company that has pioneered cheap, efficient sequencing of DNA, says it could be a reality in a few years. It is launching […]

Read More